Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ting-Ting Luo, Yi-Jin Wu, Qin Yin, Wen-Gang Chen & Jian Zuo. (2023) The Involvement of Glucose and Lipid Metabolism Alteration in Rheumatoid Arthritis and Its Clinical Implication. Journal of Inflammation Research 16, pages 1837-1852.
Read now
Read now
Takako Suzuki, Yukio Nakamura & Hiroyuki Kato. (2018) Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Modern Rheumatology 28:5, pages 885-889.
Read now
Read now
Tetsuya Kaneko, Koichi Okamura, Yukio Yonemoto, Chisa Okura, Takahito Suto, Masahiro Tachibana, Yasuyuki Tamura, Makoto Inoue & Hirotaka Chikuda. (2018) Short-term daily teriparatide in patients with rheumatoid arthritis. Modern Rheumatology 28:3, pages 468-473.
Read now
Read now
Eustathios Kenanidis, Michael E Potoupnis, Panagiotis Kakoulidis, Andreas Leonidou, Grigorios T Sakellariou, Fares E Sayegh & Eleftherios Tsiridis. (2015) Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk. Expert Opinion on Drug Safety 14:7, pages 1035-1053.
Read now
Read now
Jos N Hoes, Irene EM Bultink & Willem F Lems. (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opinion on Pharmacotherapy 16:4, pages 559-571.
Read now
Read now
Irene EM Bultink, Marijke Baden & Willem F Lems. (2013) Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy 14:2, pages 185-197.
Read now
Read now
Articles from other publishers (29)
María Lorena Brance, María Silvia Larroudé, Luis Fernando Somma, Evangelina Giacoia, María Diehl, Ana María Galich, Luis Agustín Ramirez Stieben, María Cielo Maher, María De La Vega, Ariana Ringer & Lucas R. Brun. (2023) Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy. Reumatología Clínica (English Edition) 19:5, pages 279-284.
Crossref
Crossref
María Lorena Brance, María Silvia Larroudé, Luis Fernando Somma, Evangelina Giacoia, María Diehl, Ana María Galich, Luis Agustín Ramirez Stieben, María Cielo Maher, María De La Vega, Ariana Ringer & Lucas R. Brun. (2023) Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy. Reumatología Clínica 19:5, pages 279-284.
Crossref
Crossref
Zhanna Belaya, Liudmila Rozhinskaya, Ivan Dedov, Oksana Drapkina, Valentin Fadeev, Olga Golounina, Olga Lesnyak, Elizaveta Mamedova, Galina Melnichenko, Alexey Petraikin, Svetlana Rodionova, Irina Skripnikova, Olga Tkacheva, Natalia Toroptsova, Svetlana Yureneva & John A. Kanis. (2023) A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis. Osteoporosis International 34:3, pages 429-447.
Crossref
Crossref
Satoru Mitsuboshi & Kazumasa Kotake. (2022) Risks of serious adverse events and kidney injury in patients treated with ibandronate: A systematic review and meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42:8, pages 677-686.
Crossref
Crossref
Ai Lee Lim & Swan Sim Yeap. (2022) Update on the Treatment of Glucocorticoid-Induced Osteoporosis. Journal of Clinical Rheumatology and Immunology 22:Supp01, pages 48-55.
Crossref
Crossref
Jan Leipe, Julia U. Holle, Christiane Weseloh, Alexander Pfeil & Klaus Krüger. (2021) German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosisEmpfehlungen der Deutschen Gesellschaft für Rheumatologie für die Behandlung der glukokortikoidinduzierten Osteoporose. Englische Version. Zeitschrift für Rheumatologie 80:S2, pages 49-63.
Crossref
Crossref
Jan Leipe, Julia U. Holle, Christiane Weseloh, Alexander Pfeil & Klaus Krüger. (2021) Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Management der Glukokortikoid-induzierten OsteoporoseGerman Society of Rheumatology Recommendations for the management of glucocorticoid-induced Osteoporosis. German version. Zeitschrift für Rheumatologie 80:7, pages 670-687.
Crossref
Crossref
Guido Zavatta & Bart L. Clarke. (2021) Glucocorticoid- and Transplantation-Induced Osteoporosis. Endocrinology and Metabolism Clinics of North America 50:2, pages 251-273.
Crossref
Crossref
Zhiming Liu, Min Zhang, Zhubin Shen, Junran Ke, Ding Zhang & Fei Yin. (2020) Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials. PLOS ONE 15:12, pages e0243851.
Crossref
Crossref
Liangliang Ding, Jinxi Hu, Dehua Wang, Qi Liu, Yuxia Mo, Xiang Tan & Fei Wen. (2020) Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures. The Journal of Clinical Endocrinology & Metabolism 105:3, pages 600-613.
Crossref
Crossref
Tetsuya Kaneko, Koichi Okamura, Yukio Yonemoto, Chisa Okura, Takahito Suto, Masahiro Tachibana, Hideo Sakane, Makoto Inoue & Hirotaka Chikuda. (2019) Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates. Journal of Experimental Orthopaedics 6:1.
Crossref
Crossref
Hennie G. Raterman, Irene E. M. Bultink & Willem F. Lems. (2019) Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis. Drugs 79:10, pages 1065-1087.
Crossref
Crossref
Lenore BuckleyMary B. Humphrey. (2018) Glucocorticoid-Induced Osteoporosis. New England Journal of Medicine 379:26, pages 2547-2556.
Crossref
Crossref
So Young ParkHyun Sik GongKyoung Min KimDam KimHayoung KimChan Hong JeonJi Hyeon JuShin-Seok LeeDong Ah ParkYoon-Kyoung Sung & Sang Wan Kim. (2018) Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. Journal of Rheumatic Diseases 25:4, pages 263.
Crossref
Crossref
So Young ParkHyun Sik GongKyoung Min KimDam KimHa Young KimChan Hong JeonJi Hyeon JuShin-Seok LeeDong-Ah ParkYoon-Kyoung SungSang Wan Kim. (2018) Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. Journal of Bone Metabolism 25:4, pages 195.
Crossref
Crossref
Swan Sim Yeap, Fen Lee Hew, Premitha Damodaran, Winnie Chee, Joon Kiong Lee, Emily Man Lee Goh & Siew Pheng Chan. (2017) An update of the Malaysian Clinical Guidance on the management of glucocorticoid-induced osteoporosis, 2015. Osteoporosis and Sarcopenia 3:1, pages 1-7.
Crossref
Crossref
Kichul Shin, Sung-Hwan Park, Won Park, Han Joo Baek, Yun Jong Lee, Seong Wook Kang, Jung-Yoon Choe, Wan-Hee Yoo, Yong-Beom Park, Jung-Soo Song, Seung-Geun Lee, Bin Yoo, Dae-Hyun Yoo & Yeong Wook Song. (2017) Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial. Clinical Therapeutics 39:2, pages 268-278.e2.
Crossref
Crossref
Claire S Allen, James HS Yeung, Ben Vandermeer & Joanne Homik. (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database of Systematic Reviews 2016:10.
Crossref
Crossref
E. Marco, R. Coll-Artés, M. Marín, R. Coll-Fernández, M.T. Pascual, J. Resa, L. Múñoz, M. Romero, P.M. Burnham & M. Círia. (2016) Recomendaciones sobre programas de rehabilitación pulmonar en pacientes con enfermedad pulmonar obstructiva crónica de la Sociedad de Rehabilitación Cardiorrespiratoria. Rehabilitación 50:4, pages 233-262.
Crossref
Crossref
Zeren Ma, Yong Li, Ming Zhou, Kedi Huang, Hejun Hu, Xiaoping Liu & Xiaosheng Xu. (2016) Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis. PLOS ONE 11:3, pages e0150203.
Crossref
Crossref
Tracy Lin & Jennifer Grossman. (2016) Prevention and Treatment of Bone Disease in Systemic Lupus Erythematosus. Current Treatment Options in Rheumatology 2:1, pages 21-35.
Crossref
Crossref
Cuoghi Edens & Angela Byun Robinson. (2015) Systemic lupus erythematosus, bone health, and osteoporosis. Current Opinion in Endocrinology, Diabetes & Obesity 22:6, pages 422-431.
Crossref
Crossref
Maurizio Rossini, Giovanni Orsolini, Ombretta Viapiana, Silvano Adami & Davide Gatti. (2015) Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. Endocrine 49:3, pages 620-627.
Crossref
Crossref
Yanjie Hou, Ke Gu, Chao Xu, Huiyong Ding, Changxin Liu & Yilihamu Tuoheti. (2015) Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis. Medicine 94:26, pages e1007.
Crossref
Crossref
R. A. Overman, M. L. Gourlay, C. L. Deal, J. F. Farley, M. A. Brookhart & J. B. Layton. (2015) Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporosis International 26:5, pages 1515-1524.
Crossref
Crossref
Yasuo Suzuki, Hajime Nawata, Satoshi Soen, Saeko Fujiwara, Hisanori Nakayama, Ikuko Tanaka, Keiichi Ozono, Akira Sagawa, Ryoichi Takayanagi, Hiroyuki Tanaka, Takami Miki, Naomi Masunari & Yoshiya Tanaka. (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. Journal of Bone and Mineral Metabolism 32:4, pages 337-350.
Crossref
Crossref
Natalia O Kuchuk, Jos N Hoes, Johannes WJ Bijlsma & Johannes WG Jacobs. (2014) Glucocorticoid-induced osteoporosis: an overview. International Journal of Clinical Rheumatology 9:3, pages 311-326.
Crossref
Crossref
Zhiyun Feng, Shumei Zeng, Yue Wang, Zhiyun Zheng & Zhong Chen. (2013) Bisphosphonates for the Prevention and Treatment of Osteoporosis in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis. PLoS ONE 8:12, pages e80890.
Crossref
Crossref
Swamy R. Venuturupalli & Wendy Sacks. (2013) Review of New Guidelines for the Management of Glucocorticoid Induced Osteoporosis. Current Osteoporosis Reports 11:4, pages 357-364.
Crossref
Crossref